Exclusive Summary

• **Overcoming Resistance**: The dual HER2 x Trop2 targeting strategy addresses tumor heterogeneity and antigen escape, offering a solution for patients relapsing after standard-of-care ADCs like Enhertu or Trodelvy.
• **Superior Format**: Built on a VHH (Nanobody) platform, the ~110 kDa molecule offers better tumor penetration and superior homogeneity (Pure DAR4 >95%) compared to traditional IgG-based ADCs.
• **Safety by Design**: Features 'asymmetric affinity' (High HER2, Moderate Trop2) and a clinically validated MMAE payload to significantly improve the therapeutic window and minimize ILD or skin toxicity risks.
• **Development Readiness**: Preclinical Proof-of-Concept (in vivo) is complete with a high-yield GMP stable pool (2.3 g/L) established, enabling rapid transition to IND enabling studies.

Asset Materials

Contact Us for Full Materials